Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

155.77
+1.741.13%
Volume:316.11K
Turnover:49.12M
Market Cap:15.89B
PE:22.83
High:156.18
Open:154.31
Low:153.70
Close:154.03
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.43
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.30
PE(LYR):33.35

Loading ...

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors

TIPRANKS
·
Jun 18

Neurocrine presents first retrospective case series of Crenessity

TIPRANKS
·
Jun 16

Neurocrine presents two-year Crenessity data

TIPRANKS
·
Jun 15

Neurocrine reports 2-year Phase 3 CAHtalyst Adult data showing cardiometabolic gains with CRENESSITY in classic CAH

Reuters
·
Jun 15

Vir Biotechnology names Timothy Coughlin to board, taps him as audit committee chair

Reuters
·
Jun 11

Neurocrine Biosciences director Stephen A. Sherwin disposes of USD 4.12 million in common shares

Reuters
·
Jun 10

Neurocrine director Leslie V Norwalk disposes of USD 210,071.63 in common shares

Reuters
·
Jun 09

Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug

MT Newswires Live
·
Jun 09

Neurocrine reports new post-hoc data from KINECT 4 trial

TIPRANKS
·
Jun 09

Neurocrine says post-hoc KINECT 4 data show 94% response or remission with Ingrezza in tardive dyskinesia

Reuters
·
Jun 09

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of Ingrezza® (Valbenazine) Capsules Across a Broad Range of Patients

THOMSON REUTERS
·
Jun 09

Neurocrine presents new data showing Improvements with INGREZZA

TIPRANKS
·
Jun 08

Neurocrine says clinician-reported analysis shows rapid TD improvement with Ingrezza in patients with developmental disabilities

Reuters
·
Jun 08

Neurocrine Biosciences CHRO Julie Cooke disposes of common shares worth $5.78 million

Reuters
·
Jun 05

Movement Alert|Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook

Market Focus
·
Jun 04

Neurocrine Biosciences CSO Jude Onyia disposes of common shares worth $1.76 million

Reuters
·
Jun 03

Neurocrine Biosciences Chief Regulatory Officer Ingrid Delaet disposes of 2,261 common shares for $354,323.31

Reuters
·
Jun 03

Neurocrine reinstated with a Buy at Goldman Sachs

TIPRANKS
·
Jun 02

Centene, Deckers and 14 Other 'Dividend Hopefuls' -- Barrons.com

Dow Jones
·
Jun 02